1Weverling-Rijnsburger AWE,Jonkers IJA,van Exel E,et al.High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age[J].Arch Intern Med,2003,163:1549-1554.
3Nofer J,Kehrel B,Fobker M,et al.HDL and arteriosclerosis:beyond reverse cholesterol transport[J].Atherosclerosis,2002,161:1-16.
4Nissen SE,Tsunoda T,Tuzcu EM,et al.Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes:a randomized controlled trial[J].JAMA,2003,290:2292-2300.
5American Diabetes Association.Management of dyslipidemia in adults with diabetes[J].Diabetes Care,2003,26:S83-S86.
6Sacks FM,and the Expert Group on HDL Cholesterol.The role of high-density lipoprotein(HDL) cholesterol in the prevention and treatment of coronary heart disease:expert group recommendations[J].Am J Cardiol,2002,90:139-143.
7Shepherd J,Blauw GJ,Murphy MB,et al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomized controlled trial[J].Lancet,2002,360:1623-1630.
8Heart Protection Study Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomized placebo-controlled trial[J].Lancet,2002,360:7-22.
9Ishikawa K,Tani S,Wataanabe I,et al.Effect of pravastatin on coronary plaque volume[J].Am J Cardiol,2003,92:975-977.
2Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.Circulation, 2006,113 ( 10 ):e409-449.
3Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004,350( 15 ):1495-1504.
4Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering- morning versus evening statin administration. Ann Pharmacother, 2007,41 ( 1 ): 106-110.
5Sever P,Dahlof B,Pouher N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.Eur Heart J, 2006,27 (24):2982-2988.
6Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med, 2005, 352( 14):1425-1435.
7Kapur NK.Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Rev Cardiovasc Ther, 2007,5(2):161-175.
8Sipahi I, Nicholls SJ, Tuzcu EM,et al. Coronary atherosclerosis can regress with very intensive statin therapy.Cleve Clin J Med, 2006,73( 10 ):937-944.
9Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ guidelines.Circulation,2004,110 (2): 227-239.
10Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel Ⅲ ). JAMA, 2001,285 (19): 2486-2497.
